Capricor Therapeutics (NASDAQ:CAPR) Announces Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Capricor Therapeutics (NASDAQ:CAPR) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15, Zacks reports. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.

Capricor Therapeutics Stock Up 5.3 %

NASDAQ:CAPR traded up $0.61 during trading hours on Wednesday, hitting $12.22. 1,042,031 shares of the stock were exchanged, compared to its average volume of 1,364,146. The company’s 50 day moving average is $14.09 and its two-hundred day moving average is $14.51. The company has a market capitalization of $555.64 million, a P/E ratio of -11.53 and a beta of 4.10. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Monday. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.